Railway Pension Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-15,000
Closed -$15.8M – 221
2024
Q3
$15.8M Sell
15,000
-9,000
-38% -$10M 0.19% 129
2024
Q2
$25.2M Sell
24,000
-4,100
-15% -$3.97M 0.3% 97
2024
Q1
$27M Buy
28,100
+400
+1% +$380K 0.26% 115
2023
Q4
$24.3M Sell
27,700
-54,000
-66% -$44.5M 0.25% 115
2023
Q3
$67.2M Sell
81,700
-27,300
-25% -$21.5M 0.73% 48
2023
Q2
$78.3M Sell
109,000
-28,700
-21% -$22.1M 0.78% 40
2023
Q1
$113M Buy
137,700
+11,400
+9% +$8.6M 1.16% 31
2022
Q4
$91.1M Buy
126,300
+52,300
+71% +$38.6M 0.92% 34
2022
Q3
$51M Hold
74,000
– – 0.55% 54
2022
Q2
$43.7M Buy
74,000
+29,100
+65% +$18.9M 0.43% 66
2022
Q1
$31.4M Sell
44,900
-700
-2% -$443K 0.24% 101
2021
Q4
$28.8M Buy
+45,600
New +$28M 0.22% 110
2021
Q1
– Sell
-17,100
Closed -$8.26M – 248
2020
Q4
$8.26M Sell
17,100
-26,500
-61% -$14.3M 0.08% 179
2020
Q3
$24.4M Buy
43,600
+11,200
+35% +$6.79M 0.25% 100
2020
Q2
$20.2M Buy
32,400
+17,800
+122% +$10.1M 0.23% 107
2020
Q1
$7.13M Buy
+14,600
New +$6.02M 0.1% 188

Other funds holding REGN

Railway Pension Investments's REGN Position: Q4 2024 in Review

Railway Pension Investments sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 15,000 shares — an estimated $15.8M sold.

Railway Pension Investments first reported a position in REGN in Q1 2020 and held it in 16 quarters. The position peaked at $113M in Q1 2023. 1,321 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Railway Pension Investments reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Railway Pension Investments sold 15,000 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $15.8M.
  • Railway Pension Investments first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 16 quarters.
  • Railway Pension Investments's Regeneron Pharmaceuticals position peaked at $113M in Q1 2023.
  • 1,321 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Railway Pension Investments's 13F filing for Q4 2024, filed 12 Feb 2025.